首页 > 最新文献

Seminars in Ophthalmology最新文献

英文 中文
A Global Perspective of Clinician Scientist Training Programs. 临床科学家培训计划的全球视角。
IF 1.9 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-14 DOI: 10.1080/08820538.2024.2379163
Mohammad Javed Ali
{"title":"A Global Perspective of Clinician Scientist Training Programs.","authors":"Mohammad Javed Ali","doi":"10.1080/08820538.2024.2379163","DOIUrl":"https://doi.org/10.1080/08820538.2024.2379163","url":null,"abstract":"","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-4"},"PeriodicalIF":1.9,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiation-Induced Acquired Lacrimal Drainage Obstructions: Management and Outcomes. 辐射引起的后天性泪腺引流障碍:管理和结果。
IF 1.9 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-14 DOI: 10.1080/08820538.2024.2376620
Nandini Bothra, Lisa Y Lin, Michael K Yoon

Objective: To describe the management and outcomes of patients with radiation-induced acquired lacrimal duct obstructions (RALDO).

Methods: A retrospective chart review from July 2018 to December 2023 of all cases undergoing surgical intervention for RALDO by a single surgeon. Data collected included demographics, tumor type and anatomic location, radiation treatment (including radiation type, dosage, and duration), interval between radiation and reported onset of epiphora, oculoplastic clinical examination, management, and outcomes. Lacrimal irrigation was done prior to surgery in all patients.

Results: Seventeen eyes of 16 patients with a mean age at presentation of 63.3 years and over half the patients being females (56.3%) were included in the study. The right lacrimal drainage system (LDS) was involved in 4 (23.6%), and the left side was involved in 13 (76.4%). The mean onset of epiphora symptoms after radiation was 9.5 months. The underlying tumor type were intraocular having uveal melanoma in four, cutaneous squamous cell carcinoma in 2, basal cell carcinoma involving forehead and nose in one and sino-nasal indications present in 8 patients. One patient had metastasis to the orbit and eyelid. Four patients (25%) received external beam radiotherapy (XRT) (one case had bilateral LDS involvement), 6 patients (37.5%) received intensity-modulated radiation therapy (IMRT), 5 patients (31.25%) received proton beam irradiation (PBI), and one (6.25%) received stereotactic body radiotherapy (SBRT). Mean radiation dosage was 61.31 Gy in 15 patients (data was missing in 1 patient). Punctum was effaced in 3, canalicular stenosis in 1, proximal canalicular obstruction in 8, distal canalicular obstruction in 2, and nasolacrimal duct obstruction (NLDO) in 3. Treatment was based on the site and nature of obstruction and varied from minimally invasive techniques like serial dilatation with bicanalicular silicone tube or Guibor tube to surgical interventions like dacryocystorhinostomy (DCR) or conjunctivo-dacryocystorhinostomy (C-DCR). Only 10% with primary lacrimal intubation had good response. Of the six cases that underwent C-DCR with Jones tube either as primary or secondary procedure, four cases showed improvement in epiphora (67%). Three with NLDO did well after external DCR. In total, four patients had a secondary procedure after the first failed while 7 with failed initial surgery elected against secondary surgery. The mean follow-up was 9.6 months (range 2-24 months).

Conclusions: In patients with RALDO, salvage treatment with silicone lacrimal intubation has poor results, CDCR with Jones tube has better results, although imperfect and in cases with NLDO, DCR has good outcomes.

目的描述辐射引起的获得性泪道阻塞(RALDO)患者的治疗方法和结果:对2018年7月至2023年12月期间由一名外科医生接受手术治疗的所有RALDO病例进行回顾性病历审查。收集的数据包括人口统计学、肿瘤类型和解剖位置、放射治疗(包括放射类型、剂量和持续时间)、放射治疗与报告的外窥发病之间的间隔时间、眼整形临床检查、管理和结果。所有患者在手术前均进行了泪道冲洗:本研究共纳入了 16 名患者的 17 只眼睛,患者的平均年龄为 63.3 岁,女性患者占一半以上(56.3%)。4名患者(23.6%)的泪腺引流系统(LDS)受累于右侧,13名患者(76.4%)的泪腺引流系统(LDS)受累于左侧。放射治疗后出现上睑下垂症状的平均时间为 9.5 个月。潜在肿瘤类型为眼内葡萄膜黑色素瘤(4 例)、皮肤鳞状细胞癌(2 例)、累及前额和鼻部的基底细胞癌(1 例)以及鼻窦-鼻腔适应症(8 例)。一名患者的眼眶和眼睑出现转移。四名患者(25%)接受了体外放射治疗(XRT)(其中一名患者双侧LDS受累),六名患者(37.5%)接受了调强放射治疗(IMRT),五名患者(31.25%)接受了质子束照射(PBI),一名患者(6.25%)接受了立体定向体放射治疗(SBRT)。15 名患者的平均放射剂量为 61.31 Gy(1 名患者数据缺失)。3例患者穿孔脱出,1例患者管腔狭窄,8例患者近端管腔阻塞,2例患者远端管腔阻塞,3例患者鼻泪管阻塞(NLDO)。治疗方法根据阻塞的部位和性质而定,从使用双腔硅胶管或 Guibor 管进行连续扩张等微创技术,到泪囊鼻腔造口术(DCR)或结膜-泪囊鼻腔造口术(C-DCR)等手术干预,不一而足。只有 10%的原发性泪道插管患者反应良好。在 6 例接受 C-DCR 并将琼斯管作为主要或辅助手术的病例中,有 4 例(67%)的外窥症状有所改善。3 名 NLDO 患者在接受外部 DCR 后效果良好。共有四名患者在第一次手术失败后进行了二次手术,而 7 名初次手术失败的患者则选择了放弃二次手术。平均随访时间为9.6个月(2-24个月):结论:对于 RALDO 患者,使用硅胶泪道插管进行挽救治疗效果不佳,而使用琼斯管进行 CDCR 治疗效果较好,尽管并不完美;对于 NLDO 患者,DCR 治疗效果良好。
{"title":"Radiation-Induced Acquired Lacrimal Drainage Obstructions: Management and Outcomes.","authors":"Nandini Bothra, Lisa Y Lin, Michael K Yoon","doi":"10.1080/08820538.2024.2376620","DOIUrl":"https://doi.org/10.1080/08820538.2024.2376620","url":null,"abstract":"<p><strong>Objective: </strong>To describe the management and outcomes of patients with radiation-induced acquired lacrimal duct obstructions (RALDO).</p><p><strong>Methods: </strong>A retrospective chart review from July 2018 to December 2023 of all cases undergoing surgical intervention for RALDO by a single surgeon. Data collected included demographics, tumor type and anatomic location, radiation treatment (including radiation type, dosage, and duration), interval between radiation and reported onset of epiphora, oculoplastic clinical examination, management, and outcomes. Lacrimal irrigation was done prior to surgery in all patients.</p><p><strong>Results: </strong>Seventeen eyes of 16 patients with a mean age at presentation of 63.3 years and over half the patients being females (56.3%) were included in the study. The right lacrimal drainage system (LDS) was involved in 4 (23.6%), and the left side was involved in 13 (76.4%). The mean onset of epiphora symptoms after radiation was 9.5 months. The underlying tumor type were intraocular having uveal melanoma in four, cutaneous squamous cell carcinoma in 2, basal cell carcinoma involving forehead and nose in one and sino-nasal indications present in 8 patients. One patient had metastasis to the orbit and eyelid. Four patients (25%) received external beam radiotherapy (XRT) (one case had bilateral LDS involvement), 6 patients (37.5%) received intensity-modulated radiation therapy (IMRT), 5 patients (31.25%) received proton beam irradiation (PBI), and one (6.25%) received stereotactic body radiotherapy (SBRT). Mean radiation dosage was 61.31 Gy in 15 patients (data was missing in 1 patient). Punctum was effaced in 3, canalicular stenosis in 1, proximal canalicular obstruction in 8, distal canalicular obstruction in 2, and nasolacrimal duct obstruction (NLDO) in 3. Treatment was based on the site and nature of obstruction and varied from minimally invasive techniques like serial dilatation with bicanalicular silicone tube or Guibor tube to surgical interventions like dacryocystorhinostomy (DCR) or conjunctivo-dacryocystorhinostomy (C-DCR). Only 10% with primary lacrimal intubation had good response. Of the six cases that underwent C-DCR with Jones tube either as primary or secondary procedure, four cases showed improvement in epiphora (67%). Three with NLDO did well after external DCR. In total, four patients had a secondary procedure after the first failed while 7 with failed initial surgery elected against secondary surgery. The mean follow-up was 9.6 months (range 2-24 months).</p><p><strong>Conclusions: </strong>In patients with RALDO, salvage treatment with silicone lacrimal intubation has poor results, CDCR with Jones tube has better results, although imperfect and in cases with NLDO, DCR has good outcomes.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"1-5"},"PeriodicalIF":1.9,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Variations in Citations Across Databases: Implications for Journal Impact Factors. 不同数据库中引文的变化:对期刊影响因子的影响》。
IF 1.9 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-01 Epub Date: 2024-02-28 DOI: 10.1080/08820538.2024.2322428
Khaled Moustafa

The Journal Impact Factor (JIF) is a widely used metric for ranking journals based on the number of citations garnered by papers published over a specific timeframe. To assess the accuracy of JIF values, I compared citation counts for 30 of my own publications across six major bibliography databases: CrossRef, Web of Science, Publisher records, Google Scholar, PubMed and Scopus. The analysis revealed noteworthy variations in citation counts, ranging from 10% to over 50% between the lowest and highest citation counts. Google Scholar records the highest citation numbers, while PubMed reported the lowest. Notably, Web of Science, whose citation data are used in JIF calculations, tend to underestimate citation counts compared to other databases. These observations raise concerns about the accuracy of JIF calculation based on Web of Science's citation data. The real JIF values for most journals would differ from those annually reported by Clarivate's journal citation reports (JCR). These citation discrepancies underscore the importance of comprehensive data collection and the necessity to include additional citation sources. Not because a paper is cited in one journal rather than another should it have a less or more citation weight. Ultimately, one citation remains one citation, regardless of its origin. Clarivate Analytics may thus need to consider integrating all citation sources for more accurate JIF values. Alternatively, Google Scholar could potentially develop its own journal or citation impact based on its extensive journal citation records. However, while making adjustments to how the Journal Impact Factor is calculated can make it more mathematically precise, it doesn't address the fundamental biases built into the metric. Even with refinements, the Journal Impact Factor will remain skewed due to how it's defined and used.

期刊影响因子(JIF)是一种广泛使用的期刊排名指标,它基于在特定时间范围内发表的论文所获得的引用次数。为了评估 JIF 值的准确性,我比较了自己发表的 30 篇论文在六大书目数据库中的引用次数:CrossRef、Web of Science、Publisher records、Google Scholar、PubMed 和 Scopus。分析结果显示,引用次数的变化值得注意,最低和最高的引用次数相差 10%到 50%以上不等。Google Scholar 的引用次数最高,而 PubMed 的引用次数最低。值得注意的是,与其他数据库相比,Web of Science(其引文数据被用于 JIF 计算)往往低估了引文数。这些观察结果令人担忧根据 Web of Science 的引文数据计算 JIF 的准确性。大多数期刊的真实 JIF 值都与 Clarivate 期刊引文报告 (JCR) 每年报告的数值不同。这些引文差异凸显了全面数据收集的重要性以及纳入更多引文来源的必要性。不能因为某篇论文被某本期刊引用而不被另一本期刊引用,就降低或提高其引用权重。归根结底,无论引用来源如何,引用仍然是引用。因此,Clarivate Analytics 可能需要考虑整合所有引文来源,以获得更准确的 JIF 值。另外,Google Scholar 也有可能根据其广泛的期刊引文记录,开发出自己的期刊或引文影响力。不过,虽然调整期刊影响因子的计算方法可以使其在数学上更加精确,但并不能解决该指标中存在的根本性偏差。即使进行了改进,期刊影响因子仍会因其定义和使用方式而有所偏差。
{"title":"Variations in Citations Across Databases: Implications for Journal Impact Factors.","authors":"Khaled Moustafa","doi":"10.1080/08820538.2024.2322428","DOIUrl":"10.1080/08820538.2024.2322428","url":null,"abstract":"<p><p>The Journal Impact Factor (JIF) is a widely used metric for ranking journals based on the number of citations garnered by papers published over a specific timeframe. To assess the accuracy of JIF values, I compared citation counts for 30 of my own publications across six major bibliography databases: CrossRef, Web of Science, Publisher records, Google Scholar, PubMed and Scopus. The analysis revealed noteworthy variations in citation counts, ranging from 10% to over 50% between the lowest and highest citation counts. Google Scholar records the highest citation numbers, while PubMed reported the lowest. Notably, Web of Science, whose citation data are used in JIF calculations, tend to underestimate citation counts compared to other databases. These observations raise concerns about the accuracy of JIF calculation based on Web of Science's citation data. The real JIF values for most journals would differ from those annually reported by Clarivate's journal citation reports (JCR). These citation discrepancies underscore the importance of comprehensive data collection and the necessity to include additional citation sources. Not because a paper is cited in one journal rather than another should it have a less or more citation weight. Ultimately, one citation remains one citation, regardless of its origin. Clarivate Analytics may thus need to consider integrating all citation sources for more accurate JIF values. Alternatively, Google Scholar could potentially develop its own journal or citation impact based on its extensive journal citation records. However, while making adjustments to how the Journal Impact Factor is calculated can make it more mathematically precise, it doesn't address the fundamental biases built into the metric. Even with refinements, the Journal Impact Factor will remain skewed due to how it's defined and used.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"400-403"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139983691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Taser-Related Ocular Injuries: A Review of the Literature and Medico-Legal Implications. 泰瑟枪导致的眼部伤害:文献综述和医学法律意义。
IF 1.7 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-19 DOI: 10.1080/08820538.2024.2322452
Giovanni Aulino, Federico Giannuzzi, Matteo Mario Carlà, Giorgia Guarnieri, Domenico Spagnolo, Domenico Lepore, Francesca Cittadini, Stanislao Rizzo

Purpose: Electric weapons have dangers associated with their use, such as burns and trauma related with the impacts of uncontrolled falls, even though they often minimize morbidity and mortality. The exact visual outcome of the damage inflicted is unknown, even though numerous studies have been documented in the literature about the ocular damage induced by the use of these tools.

Methods: We present a narrative review of types of eye damage associated with the use of the Taser. The following search terms were used to identify eligible articles through the PubMed database: "TASER", "Conducted Electric Weapons", "CEWs".

Results: A total of 15 articles were included with information about 38 patients with eye damage associated with the use of taser. The majority of patients were males. In most cases the mechanism of injury was the penetration of the probe inside the eye. Clinical manifestations of ocular damage were present in only 18 out of 38 cases and varied according to the type of damage mechanism. Indeed, the cases in which the probe had penetrated the eye showed more severe clinical manifestations with a poor visual outcome.

Conclusion: In conclusion, the introduction of taser use for law enforcement requires serious consideration and adequate training for officers.

目的:使用电动武器有一定的危险性,如烧伤和与失控坠落的冲击力有关的创伤,尽管它们通常能最大限度地降低发病率和死亡率。尽管文献中记载了大量有关使用这些工具造成眼部损伤的研究,但所造成损伤的确切视力结果仍不得而知:我们对与使用泰瑟枪有关的眼部损伤类型进行了叙述性综述。在 PubMed 数据库中,我们使用以下检索词来确定符合条件的文章:"TASER"、"Conducted Electric Weapons"、"CEWs":结果:共收录了 15 篇文章,涉及 38 名因使用泰瑟枪而导致眼部损伤的患者。大多数患者为男性。在大多数情况下,伤害机制是探针刺入眼内。在 38 例患者中,只有 18 例出现了眼部损伤的临床表现,并且根据损伤机制的类型而有所不同。事实上,探针穿透眼球的病例临床表现更为严重,视力状况不佳:总之,在执法过程中使用泰瑟枪需要认真考虑,并对执法人员进行充分培训。
{"title":"Taser-Related Ocular Injuries: A Review of the Literature and Medico-Legal Implications.","authors":"Giovanni Aulino, Federico Giannuzzi, Matteo Mario Carlà, Giorgia Guarnieri, Domenico Spagnolo, Domenico Lepore, Francesca Cittadini, Stanislao Rizzo","doi":"10.1080/08820538.2024.2322452","DOIUrl":"10.1080/08820538.2024.2322452","url":null,"abstract":"<p><strong>Purpose: </strong>Electric weapons have dangers associated with their use, such as burns and trauma related with the impacts of uncontrolled falls, even though they often minimize morbidity and mortality. The exact visual outcome of the damage inflicted is unknown, even though numerous studies have been documented in the literature about the ocular damage induced by the use of these tools.</p><p><strong>Methods: </strong>We present a narrative review of types of eye damage associated with the use of the Taser. The following search terms were used to identify eligible articles through the PubMed database: \"TASER\", \"Conducted Electric Weapons\", \"CEWs\".</p><p><strong>Results: </strong>A total of 15 articles were included with information about 38 patients with eye damage associated with the use of taser. The majority of patients were males. In most cases the mechanism of injury was the penetration of the probe inside the eye. Clinical manifestations of ocular damage were present in only 18 out of 38 cases and varied according to the type of damage mechanism. Indeed, the cases in which the probe had penetrated the eye showed more severe clinical manifestations with a poor visual outcome.</p><p><strong>Conclusion: </strong>In conclusion, the introduction of taser use for law enforcement requires serious consideration and adequate training for officers.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"334-339"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140158969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corneal Hysteresis as a Marker for Patients with Secondary Glaucoma. 作为继发性青光眼患者标志的角膜滞后。
IF 1.7 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-11 DOI: 10.1080/08820538.2024.2322443
Marko Oydanich, Aditya Uppuluri, Hadeel Sadek, Albert S Khouri

Purpose: To investigate and compare the association of corneal hysteresis (CH) in patients with secondary glaucoma to control patients and patients with primary open-angle glaucoma (POAG). Additionally, to determine the consistency of CH measurements in patients with secondary glaucoma.

Methods: A total of 84 patients (121 eyes) were prospectively included in this study. Twenty-three patients (46 eyes) were healthy controls, 24 patients (40 eyes) were diagnosed with POAG, and 27 patients (35 eyes) were diagnosed with a form of secondary glaucoma. CH and intraocular pressure (IOP) were measured using the Ocular Response Analyzer. Three measurements per eye were performed and used for the analysis and to determine fluctuations in CH data. One-way ANOVA with post-hoc Bonferroni analysis and Chi-Squared testing was done to determine differences between groups.

Results: All patients were matched for age. Patients in both POAG and secondary glaucoma groups were matched for age and IOP. All groups had similar sex and racial compositions as well as similar proportions of diabetes, hypertension, and hyperlipidemia. CH was lower (p < .05) in patients with POAG (9.32 ± 1.64) and secondary glaucoma (7.89 ± 3.18) when compared to healthy controls (11.16 ± 1.60). Fluctuations in CH measurements were minimal in all groups. Further analysis of the secondary glaucoma group revealed no differences in CH between different types of secondary glaucoma (p > .05).

Conclusion: Patients with secondary glaucoma have lower CH when compared to POAG or control groups. The ORA exhibits precision of CH measurements for control, POAG, and secondary glaucoma groups, making it a reliable tool in management of secondary forms of glaucoma.

目的:调查并比较继发性青光眼患者与对照组患者和原发性开角型青光眼(POAG)患者的角膜滞后(CH)相关性。此外,还要确定继发性青光眼患者角膜滞后测量的一致性:本研究共纳入了 84 名患者(121 只眼)。23名患者(46只眼)为健康对照组,24名患者(40只眼)被诊断为POAG,27名患者(35只眼)被诊断为继发性青光眼。CH和眼压(IOP)使用眼部反应分析仪进行测量。每只眼睛进行三次测量,用于分析和确定 CH 数据的波动。采用单因素方差分析、事后Bonferroni分析和Chi-Squared检验来确定组间差异:所有患者的年龄均匹配。POAG 组和继发性青光眼组患者的年龄和眼压均匹配。所有组别的性别和种族构成相似,糖尿病、高血压和高脂血症的比例也相似。结论:结论:与 POAG 或对照组相比,继发性青光眼患者的 CH 值较低。ORA对对照组、POAG组和继发性青光眼组的CH测量精确,是继发性青光眼管理的可靠工具。
{"title":"Corneal Hysteresis as a Marker for Patients with Secondary Glaucoma.","authors":"Marko Oydanich, Aditya Uppuluri, Hadeel Sadek, Albert S Khouri","doi":"10.1080/08820538.2024.2322443","DOIUrl":"10.1080/08820538.2024.2322443","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate and compare the association of corneal hysteresis (CH) in patients with secondary glaucoma to control patients and patients with primary open-angle glaucoma (POAG). Additionally, to determine the consistency of CH measurements in patients with secondary glaucoma.</p><p><strong>Methods: </strong>A total of 84 patients (121 eyes) were prospectively included in this study. Twenty-three patients (46 eyes) were healthy controls, 24 patients (40 eyes) were diagnosed with POAG, and 27 patients (35 eyes) were diagnosed with a form of secondary glaucoma. CH and intraocular pressure (IOP) were measured using the Ocular Response Analyzer. Three measurements per eye were performed and used for the analysis and to determine fluctuations in CH data. One-way ANOVA with post-hoc Bonferroni analysis and Chi-Squared testing was done to determine differences between groups.</p><p><strong>Results: </strong>All patients were matched for age. Patients in both POAG and secondary glaucoma groups were matched for age and IOP. All groups had similar sex and racial compositions as well as similar proportions of diabetes, hypertension, and hyperlipidemia. CH was lower (<i>p</i> < .05) in patients with POAG (9.32 ± 1.64) and secondary glaucoma (7.89 ± 3.18) when compared to healthy controls (11.16 ± 1.60). Fluctuations in CH measurements were minimal in all groups. Further analysis of the secondary glaucoma group revealed no differences in CH between different types of secondary glaucoma (<i>p</i> > .05).</p><p><strong>Conclusion: </strong>Patients with secondary glaucoma have lower CH when compared to POAG or control groups. The ORA exhibits precision of CH measurements for control, POAG, and secondary glaucoma groups, making it a reliable tool in management of secondary forms of glaucoma.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"376-380"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 1.7 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-29 DOI: 10.1080/08820538.2024.2348326
{"title":"Correction.","authors":"","doi":"10.1080/08820538.2024.2348326","DOIUrl":"https://doi.org/10.1080/08820538.2024.2348326","url":null,"abstract":"","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":"39 5","pages":"404-405"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Multi-Parameters Combination of Technetium-99m-Diethylene-Triamine-Pentaacetate Orbital Single-Photon Emission Computed Tomography/Computed Tomography for the Evaluation of Graves' Orbitopathy Activity. 锝-99m-二乙撑三胺-五乙酸酯眼眶单光子发射计算机断层扫描/计算机断层扫描多参数新组合用于评估巴塞杜氏眼眶病的活动。
IF 1.7 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-01 Epub Date: 2024-02-27 DOI: 10.1080/08820538.2024.2324070
Lixin Sun, Ruchen Peng, Rongxin Sun

Purpose: This study investigates the new combined parameters of 99mTc-DTPA orbital single-photon emission computed tomography/computed tomography (SPECT/CT) for the evaluation of Graves' orbitopathy (GO) activity.

Methods: A retrospective analysis was performed on 41 patients. All the patients undergone the 99mTc-DTPA orbital SPECT/CT and were categorized into active and inactive group based on the standard combined by the clinical active score (CAS), magnet resonance imaging (MRI) and/or follow-up results. Quantitative parameters of lacrimal gland (LG) including the protruding degree of lacrimal gland herniation (LGH) and uptake ratios (URs) of region of interest (ROI) drawn on lacrimal gland and occipital bone. SPECT/CT reading results were based on visual analysis. Parameters were compared between the two groups and the diagnostic value on discrimination of GO activity was also evaluated.

Results: All parameters of SPECT/CT for active GO groups were significantly higher than those of the inactive groups (p<.05). There were notable linear positive correlations between the assumption standard and readings as well as combination models 2 and 3 (r = .794, r = .772, r = .760, respectively). ROC analysis indicated that model 2 provided the highest diagnostic performance, exhibiting an area under the curve (AUC) of .947, a sensitivity of 92.7%, and a specificity of 88.6%.

Conclusions: The combined use of SPECT/CT reading results and DTPA uptake parameters of LG offers a more objective and precise evaluation of active GO. This study further recommends 99mTc-DTPA SPECT/CT might be serving as a supplementary beneficial approach for CAS in evaluating GO activity.

目的:本研究探讨了99m锝-DTPA眼眶单光子发射计算机断层扫描/计算机断层扫描(SPECT/CT)用于评估巴塞杜氏眼眶病(GO)活动性的新组合参数:对41名患者进行了回顾性分析。所有患者均接受了99m锝-DTPA眼眶SPECT/CT检查,并根据临床活动评分(CAS)、磁共振成像(MRI)和/或随访结果的标准将其分为活动组和非活动组。泪腺(LG)的定量参数包括泪腺突出程度(LGH)以及泪腺和枕骨感兴趣区(ROI)的摄取比(URs)。SPECT/CT阅读结果以目测分析为基础。对两组患者的参数进行了比较,并评估了GO活动的诊断价值:结果:GO活动组的SPECT/CT所有参数均明显高于非活动组(pr=.794,r=.772,r=.760)。ROC分析表明,模型2的诊断性能最高,其曲线下面积(AUC)为0.947,灵敏度为92.7%,特异度为88.6%:结论:结合使用 SPECT/CT 读数结果和 LG 的 DTPA 摄取参数,可以更客观、更精确地评估活动性 GO。本研究进一步建议,99m锝-DTPA SPECT/CT 可作为 CAS 评估 GO 活动性的有益补充方法。
{"title":"New Multi-Parameters Combination of Technetium-99m-Diethylene-Triamine-Pentaacetate Orbital Single-Photon Emission Computed Tomography/Computed Tomography for the Evaluation of Graves' Orbitopathy Activity.","authors":"Lixin Sun, Ruchen Peng, Rongxin Sun","doi":"10.1080/08820538.2024.2324070","DOIUrl":"10.1080/08820538.2024.2324070","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates the new combined parameters of <sup>99m</sup>Tc-DTPA orbital single-photon emission computed tomography/computed tomography (SPECT/CT) for the evaluation of Graves' orbitopathy (GO) activity.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 41 patients. All the patients undergone the 99mTc-DTPA orbital SPECT/CT and were categorized into active and inactive group based on the standard combined by the clinical active score (CAS), magnet resonance imaging (MRI) and/or follow-up results. Quantitative parameters of lacrimal gland (LG) including the protruding degree of lacrimal gland herniation (LGH) and uptake ratios (URs) of region of interest (ROI) drawn on lacrimal gland and occipital bone. SPECT/CT reading results were based on visual analysis. Parameters were compared between the two groups and the diagnostic value on discrimination of GO activity was also evaluated.</p><p><strong>Results: </strong>All parameters of SPECT/CT for active GO groups were significantly higher than those of the inactive groups (<i>p</i><.05). There were notable linear positive correlations between the assumption standard and readings as well as combination models 2 and 3 (<i>r</i> = .794, <i>r</i> = .772, <i>r</i> = .760, respectively). ROC analysis indicated that model 2 provided the highest diagnostic performance, exhibiting an area under the curve (AUC) of .947, a sensitivity of 92.7%, and a specificity of 88.6%.</p><p><strong>Conclusions: </strong>The combined use of SPECT/CT reading results and DTPA uptake parameters of LG offers a more objective and precise evaluation of active GO. This study further recommends <sup>99m</sup>Tc-DTPA SPECT/CT might be serving as a supplementary beneficial approach for CAS in evaluating GO activity.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"387-393"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139973353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pilot Study Assessing the Safety and Acceptance of a Novel Virtual Reality System to Improve Visual Function. 评估用于改善视觉功能的新型虚拟现实系统的安全性和接受度的试点研究。
IF 1.7 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-01 DOI: 10.1080/08820538.2024.2324074
Luis Leal-Vega, David P Piñero, Ainhoa Molina-Martín, Carlos J Hernández-Rodríguez, Rubén Cuadrado-Asensio, Adrián Martín-Gutiérrez, Juan Francisco Arenillas Lara, María Begoña Coco Martín

Purpose: To assess the feasibility of the clinical use of a novel Virtual Reality (VR) training software designed to be used for active vision therapy in amblyopic patients by determining its preliminary safety and acceptance on the visual function of healthy adults.

Methods: Pilot study enrolling 10 individuals (3 men, 7 women, mean age: 31.8 ± 6.5 years) with a best-corrected visual acuity (BCVA) of ≥ .90 (decimal) in both eyes were evaluated before and after 20 minutes of exposure to the NEIVATECH VR system using the HTC Vive Pro Eye head mounted display. Visual function assessment included near (40 cm) and distance (6 m) cover test (CT), stereopsis, binocular accommodative facility (BAF), near point of convergence (NPC), near point of accommodation (NPA), accommodative-convergence over accommodation (AC/A) ratio and positive and negative fusional vergences. Safety was assessed using the VR Sickness Questionnaire (VRSQ) and acceptance using the Technology Acceptance Model ;(TAM). Changes in all these variables after VR exposure were analyzed.

Results: Short-term exposure to the NEIVATECH VR system only induced statistically significant changes in distance phoria (p = .016), but these changes were not clinically relevant. No significant changes were observed in VRSQ oculo-motricity and disorientation scores after exposure (p = .197 and .317, respectively). TAM scores showed a good acceptance of the system in terms of perceived enjoyment and perceived ease of use, although some concerns were raised in relation to the intention-to-use domain.

Conclusion: Exposure to the NEIVATECH VR system does not seem to adversely affect the visual function in healthy adults and its safety and acceptance profile seems to be adequate for supporting its potential use in other populations, such as amblyopic patients.

目的:评估新型虚拟现实(VR)训练软件用于弱视患者主动视力治疗的临床应用可行性,确定其对健康成年人视觉功能的初步安全性和接受度:试点研究招募了 10 名双眼最佳矫正视力 (BCVA) 均≥ 0.90(十进制)的患者(3 名男性,7 名女性,平均年龄:31.8 ± 6.5 岁),在使用 HTC Vive Pro Eye 头戴式显示器接触 NEIVATECH VR 系统 20 分钟前后进行评估。视觉功能评估包括近距离(40 厘米)和远距离(6 米)遮盖测试(CT)、立体视、双眼容纳设施(BAF)、近辐辏点(NPC)、近调节点(NPA)、容纳-辐辏大于调节(AC/A)比率以及正负融合眩晕。安全性采用 VR 晕眩问卷(VRSQ)进行评估,接受度采用技术接受模型(TAM)进行评估。对所有这些变量在接触 VR 后的变化进行了分析:结果:短期暴露于 NEIVATECH VR 系统仅在距离幻觉方面引起了统计学意义上的显著变化(p = .016),但这些变化与临床无关。暴露后,VRSQ 的眼球运动性和迷失方向评分没有明显变化(p = .197 和 .317)。TAM评分显示,在感知乐趣和感知易用性方面,受试者对该系统的接受度较高,但在使用意向方面存在一些问题:结论:接触 NEIVATECH VR 系统似乎不会对健康成年人的视觉功能产生不利影响,其安全性和接受度似乎足以支持其在弱视患者等其他人群中的潜在应用。
{"title":"Pilot Study Assessing the Safety and Acceptance of a Novel Virtual Reality System to Improve Visual Function.","authors":"Luis Leal-Vega, David P Piñero, Ainhoa Molina-Martín, Carlos J Hernández-Rodríguez, Rubén Cuadrado-Asensio, Adrián Martín-Gutiérrez, Juan Francisco Arenillas Lara, María Begoña Coco Martín","doi":"10.1080/08820538.2024.2324074","DOIUrl":"10.1080/08820538.2024.2324074","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the feasibility of the clinical use of a novel Virtual Reality (VR) training software designed to be used for active vision therapy in amblyopic patients by determining its preliminary safety and acceptance on the visual function of healthy adults.</p><p><strong>Methods: </strong>Pilot study enrolling 10 individuals (3 men, 7 women, mean age: 31.8 ± 6.5 years) with a best-corrected visual acuity (BCVA) of ≥ .90 (decimal) in both eyes were evaluated before and after 20 minutes of exposure to the NEIVATECH VR system using the HTC Vive Pro Eye head mounted display. Visual function assessment included near (40 cm) and distance (6 m) cover test (CT), stereopsis, binocular accommodative facility (BAF), near point of convergence (NPC), near point of accommodation (NPA), accommodative-convergence over accommodation (AC/A) ratio and positive and negative fusional vergences. Safety was assessed using the VR Sickness Questionnaire (VRSQ) and acceptance using the Technology Acceptance Model ;(TAM). Changes in all these variables after VR exposure were analyzed.</p><p><strong>Results: </strong>Short-term exposure to the NEIVATECH VR system only induced statistically significant changes in distance phoria (<i>p</i> = .016), but these changes were not clinically relevant. No significant changes were observed in VRSQ oculo-motricity and disorientation scores after exposure (<i>p</i> = .197 and .317, respectively). TAM scores showed a good acceptance of the system in terms of perceived enjoyment and perceived ease of use, although some concerns were raised in relation to the intention-to-use domain.</p><p><strong>Conclusion: </strong>Exposure to the NEIVATECH VR system does not seem to adversely affect the visual function in healthy adults and its safety and acceptance profile seems to be adequate for supporting its potential use in other populations, such as amblyopic patients.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"394-399"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity. COVID-19 后脉络膜视网膜病变:系统性回顾和患病率评估,揭示新出现的眼部疾病的内涵。
IF 1.9 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-11 DOI: 10.1080/08820538.2024.2323113
Mona Mahmoud Elsakka, Mostafa Hossam El Din Moawad, Eman E Labeeb, Mohamed Elneny, Abdelmonem Siddiq, Shereen Gahlan, Ibraheem M Alkhawaldeh, Hashem Abu Serhan

Purpose: To investigate the occurrence of chorioretinopathy post-COVID-19, emphasizing demographic characteristics, medication history, clinical presentation, diagnostic evaluation, and treatment approaches, with a specific focus on the role of corticosteroid use.

Methods: Our protocol was registered prospectively on PROSPERO (CRD42023457712). A systematic search of databases (PubMed, Cochrane, WOS, Scopus) from November 2020 to August 2023 were performed to identify any original research reporting chorioretinopathy in COVID-19 patients. Data extraction included patient demographics, COVID-19 timeline, medication history, symptoms, diagnostic tests, and treatment outcomes. We used Joanna Briggs Institute (JBI) critical appraisal tool to assess the quality of our included studies.

Results: We identified seven case reports and two case series including 10 patients, six females and four males (mean age 36.5 years), who exhibited chorioretinopathy after COVID-19. Onset varied from 6 days to three months post-infection (average = 24.3 days). Seven patients (70%) had a history of corticosteroid use during COVID-19 treatment. Symptoms included visual loss, blurred vision, and deterioration. Diagnostic assessments revealed central serous chorioretinopathy in seven patients (70%) and punctate inner choroidopathy in two (20%). Treatment approaches varied, with corticosteroid discontinuation leading to symptom improvement, while two patients were treated with corticosteroids. Five patients who discontinued corticosteroids were reported to have improvement in visual acuity, two of them changed to 20/25 after being 20/40, two changed to 6/6, and one changed to 20/20, while the visual acuity in the sixth patient was not reported. Regarding the two patients who were treated with corticosteroids, visual acuity was reported in one case only and it improved to 20/20.

Conclusion: This systematic review states the prevalence and potential association between chorioretinopathy, and corticosteroid use in the context of COVID-19. This relation is still unclear because of the relief of symptoms in some cases after corticosteroid discontinuation, while two other cases were treated with corticosteroids and their symptoms improved.

目的:调查COVID-19后脉络膜视网膜病变的发生情况,重点关注人口统计学特征、用药史、临床表现、诊断评估和治疗方法,尤其关注皮质类固醇使用的作用:我们的方案在 PROSPERO(CRD42023457712)上进行了前瞻性注册。我们对 2020 年 11 月至 2023 年 8 月期间的数据库(PubMed、Cochrane、WOS、Scopus)进行了系统检索,以确定任何报道 COVID-19 患者脉络膜视网膜病变的原创性研究。数据提取包括患者人口统计学特征、COVID-19 时间轴、用药史、症状、诊断测试和治疗结果。我们使用乔安娜-布里格斯研究所(Joanna Briggs Institute,JBI)的批判性评价工具来评估纳入研究的质量:结果:我们发现了七份病例报告和两份系列病例,其中包括 10 名患者,六名女性和四名男性(平均年龄 36.5 岁),他们在 COVID-19 后出现了脉络膜视网膜病变。发病时间从感染后 6 天到三个月不等(平均 = 24.3 天)。七名患者(70%)在 COVID-19 治疗期间曾使用过皮质类固醇。症状包括视力下降、视力模糊和视力衰退。诊断评估显示,七名患者(70%)患有中心性浆液性脉络膜视网膜病变,两名患者(20%)患有点状内脉络膜病变。治疗方法各不相同,停用皮质类固醇后症状有所改善,但仍有两名患者接受了皮质类固醇治疗。据报告,5 名停用皮质类固醇的患者视力有所改善,其中 2 人的视力从 20/40 改为 20/25,2 人的视力为 6/6,1 人的视力为 20/20,而第 6 名患者的视力没有报告。至于接受皮质类固醇治疗的两名患者,仅报告了其中一例患者的视力改善至 20/20:本系统综述说明了脉络膜视网膜病变的发病率以及在 COVID-19 的背景下使用皮质类固醇之间的潜在联系。由于一些病例在停用皮质类固醇后症状有所缓解,而另外两个病例在接受皮质类固醇治疗后症状有所改善,因此这种关系尚不明确。
{"title":"Chorioretinopathy Post COVID-19: A Systematic Review and Prevalence Assessment, Unveiling Insights into an Emerging Ocular Entity.","authors":"Mona Mahmoud Elsakka, Mostafa Hossam El Din Moawad, Eman E Labeeb, Mohamed Elneny, Abdelmonem Siddiq, Shereen Gahlan, Ibraheem M Alkhawaldeh, Hashem Abu Serhan","doi":"10.1080/08820538.2024.2323113","DOIUrl":"10.1080/08820538.2024.2323113","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the occurrence of chorioretinopathy post-COVID-19, emphasizing demographic characteristics, medication history, clinical presentation, diagnostic evaluation, and treatment approaches, with a specific focus on the role of corticosteroid use.</p><p><strong>Methods: </strong>Our protocol was registered prospectively on PROSPERO (CRD42023457712). A systematic search of databases (PubMed, Cochrane, WOS, Scopus) from November 2020 to August 2023 were performed to identify any original research reporting chorioretinopathy in COVID-19 patients. Data extraction included patient demographics, COVID-19 timeline, medication history, symptoms, diagnostic tests, and treatment outcomes. We used Joanna Briggs Institute (JBI) critical appraisal tool to assess the quality of our included studies.</p><p><strong>Results: </strong>We identified seven case reports and two case series including 10 patients, six females and four males (mean age 36.5 years), who exhibited chorioretinopathy after COVID-19. Onset varied from 6 days to three months post-infection (average = 24.3 days). Seven patients (70%) had a history of corticosteroid use during COVID-19 treatment. Symptoms included visual loss, blurred vision, and deterioration. Diagnostic assessments revealed central serous chorioretinopathy in seven patients (70%) and punctate inner choroidopathy in two (20%). Treatment approaches varied, with corticosteroid discontinuation leading to symptom improvement, while two patients were treated with corticosteroids. Five patients who discontinued corticosteroids were reported to have improvement in visual acuity, two of them changed to 20/25 after being 20/40, two changed to 6/6, and one changed to 20/20, while the visual acuity in the sixth patient was not reported. Regarding the two patients who were treated with corticosteroids, visual acuity was reported in one case only and it improved to 20/20.</p><p><strong>Conclusion: </strong>This systematic review states the prevalence and potential association between chorioretinopathy, and corticosteroid use in the context of COVID-19. This relation is still unclear because of the relief of symptoms in some cases after corticosteroid discontinuation, while two other cases were treated with corticosteroids and their symptoms improved.</p>","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"353-363"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Readership Awareness Series - Paper 10: Open Access Publishing. 读者意识丛书--论文 10:开放存取出版。
IF 1.7 4区 医学 Q2 OPHTHALMOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-25 DOI: 10.1080/08820538.2024.2333644
Mohammad Javed Ali, Djalilian Ali
{"title":"Readership Awareness Series - Paper 10: Open Access Publishing.","authors":"Mohammad Javed Ali, Djalilian Ali","doi":"10.1080/08820538.2024.2333644","DOIUrl":"10.1080/08820538.2024.2333644","url":null,"abstract":"","PeriodicalId":21702,"journal":{"name":"Seminars in Ophthalmology","volume":" ","pages":"331-333"},"PeriodicalIF":1.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140207578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Seminars in Ophthalmology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1